Veritas Announces Private Placement

January 9, 2017, Vancouver, B.C. – Veritas Pharma Inc. (the “Company”) (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), is pleased to announce that a non-brokered private placement offering of up to 9,090,910 units (“Units”) at a price of $0.22 per Unit for aggregate gross proceeds of up to $2,000,000 (the “Offering”) Each Unit is comprised of one common share ("Share") and one Share purchase warrant of the Company ("Warrant"). Each whole Warrant will entitle the holder to purchase one Share (a "Warrant Share") at an exercise price of $0.30 per Warrant Share for a period of 18 months from the date of issuance. In the event that the closing price (or closing bid, if no sales were reported on a trading day) of the Company's Shares as quoted on the Canadian Securities Exchange (the "Exchange") or such other securities exchange, quotation system or market on which the Shares are listed and where a majority of the trading volume of the Shares occurs) exceeds $0.80 per Share for a price of ten consecutive trading days, the Company may, within five days of such event, provide notice by way of news release of early expiry, in which event the Warrants will expire 30 days from the date of such news release.

The Company may, in its sole discretion, pay a finder's fee to agents of the Company: (i) a cash fee in an amount of 8% of the proceeds raised by such finder as part of this Offering (including any proceeds pursuant to the Over-Allotment Option), and (ii) a number of finder's options entitling the holder thereof to purchase that number of Units of the Company ("Finder's Unit") that is equal up to 8% of the number of Units placed through the finder as part of this Offering (including any proceeds pursuant to the Over-Allotment Option).

The proceeds from the financing will be used to complete the acquisition of Cannevert Therapeutics Ltd. (“CTL”) and for working capital purposes.

About Veritas Pharma Inc.

Veritas Pharma Inc. is an emerging discovery and IP development company, committed to advancing the science behind medical cannabis. The company’s current R&D effortsare being conducted through its strategic partner, CTL. The ultimate objectives of our R&D efforts are to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for real science to support medical marijuana claims.

About Cannevert Therapeutics Ltd.

CTL is a private company owned by a unique group of chemists, pharmacologists, and other medical science professionals. With offices located on the campus of the University of British Columbia, CTL has obtained permission from Health Canada to conduct research on cannabis strains. CTL has entered a funding agreement with Veritas where,  upon advancing $1.5 million to CTL, Veritas will earn an 80% ownership interest in CTL.

To date, Veritas has advanced $1,000,000 to CTL and holds contingent ownership of, but not the voting rights over, 53.3% of the issued and outstanding common shares of CTL.

Veritas will not acquire full ownership rights, including voting rights, over any CTL common shares until the entire $1.5 million has been paid. CTL has also entered a licensing agreement with Veritas, licensing Veritas to market all products developed by CTL.

Veritas’ and CTL’s unique value proposition employs a whole plant methodology, using a low-cost research and development model to help drive shareholder value and speed-to market. The company’s commercial mission is to patent protect its IP (cultivars/ strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets.

Veritas Pharma Inc. is a publicly traded company, which trades in three countries including Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.

For more information, please visit our website: www.veritaspharmainc.com

On behalf of the Board of Directors; Veritas Pharma Inc.

"Dr. Lui Franciosi"

Dr. Lui Franciosi

Chief Executive Officer

Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com

Investor and Public Relations Contact

Veritas Pharma Inc.

Sam Eskandari

Telephone: +1.416.918.6785

Email: ir@veritaspharmainc.com

Website: www.veritaspharmainc.com

The CSE has not reviewed, nor approved or disapproved the content of this press release.

Veritas Pharma Enters into Agreement to Secure ACMPR License and Cannabis Growing Facility

Nov 21, 2016 | News

VANCOUVER, November 21, 2016, Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), (“Veritas” or the “Company”), an emerging-stage pharmaceutical and IP development company, is pleased to announce that it has signed a Letter of Intent (“LOI”) with Sechelt Organic Marijuana Inc. (“Privco”), whereby Veritas has been granted the exclusive option to acquire 100% ownership of PrivCo (the “Transaction”), subject to certain terms and conditions including; obtaining an ACMPR/MMPR license and the issuance of a permit by Health Canada for the building of a cannabis growing facility. Further, and as part of the agreement, Veritas will manage and help facilitate the application process with Health Canada, and will pay all out-of-pocket expenses during the approval process.

The target acquisition (“PrivCo”), currently owns a secure commercial facility and land located in Sechelt, British Columbia, Canada and, since July 4, 2014, has had an application pending with Health Canada for a new MMPR (Marihuana for Medical Purposes Regulations) license. PrivCo personnel includes an experienced grow master who is currently a ‘designated grower’ under current MMAR licensing guidelines.

Dr. Lui Franciosi (CEO, Veritas Pharma) comments, “This is a win-win scenario for Veritas and its shareholders. We believe this transaction is both tactical and value driven. Further and most importantly, it is representative of the steps we will take to secure and maximize our position along the medical marijuana supply chain.

We are making great strides advancing R&D through our investment in Cannevert Therapeutics Ltd. (“CTL”), targeting pain, nausea and PTSD solutions. This strategic acquisition will bring together our valuable IP surrounding our disease specific medical marijuana strains.” Dr. Franciosi continues…”With this acquisition, Veritas will control and have ownership of the entire process from developing our patented strains through Cannevert, to cultivation, thereby ensuring our medical marijuana product is ready for market, that is backed by scientific data.”

Under the terms of the LOI, Veritas Pharma has the option of acquiring 100% of the issued and outstanding shares of PrivCo.  Once Health Canada grants to PrivCo the permit to build a cannabis-growing facility and to issue to PrivCo the requisite MMPR license, Veritas will proceed to close the option to acquire PrivCo within 60 days of the approval, to Close the acquisition by making a cash payment of $400,000 for the land and facilities, as well as a common stock payment equivalent to $400,000 for the MMPR license.

The assignment is subject to Exchange approval.

On November 16, 2016, Veritas announced an increase to its planned private placement. The private placement will be for total of 4,750,000 units (“Units”) at a price of $0.30 per Unit for aggregate gross proceeds of up to $1,425,000 (the “offering”). Each Unit will be comprised of one common share (“Share”) and one-half Share purchase warrant of the company (a “Warrant Share”) at an exercise price of $0.50 per Warrant Share for a period of 18 months from the date of issuance.  All additional terms and conditions of the Offering will remain the same as the announcement on September 16th, 2016.  In addition, to this private placement Veritas board has decided to grant stock options to consultants to purchase 500,000 shares of VRT at exercisable price of $0.45.

About Veritas Pharma Inc.

Veritas Pharma Inc. is an emerging-stage pharmaceutical and IP development company, who, through CTL, is advancing the science behind medical cannabis. It is the Company aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims.  CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect CTL’s IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets.

About Cannevert Therapeutics Ltd.

CTL is a private company owned by a unique group of chemists, pharmacologists, and other medical professionals. With offices located on the campus of the University of British Columbia, CTL has obtained permission from Health Canada to conduct research on cannabis strains. CTL has entered a funding agreement with Veritas where, upon advancing $1.5 million to CTL, Veritas will earn an 80% ownership interest in CTL. Although Veritas has advanced $750,000 to CTL, no ownership interest will be earned by Veritas until the entire $1.5 million is received. CTL has also entered a licensing agreement with Veritas, licensing Veritas to market all products developed by CTL.

Veritas Pharma Inc. is a publicly traded company which trades in three countries including Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.

For more information, please visit our website: veritaspharmainc.com

On behalf of the Board of Directors

Veritas Pharma Inc.
“Dr. Lui Franciosi”Dr. Lui Franciosi
Chief Executive Officer
Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: ir@veritaspharmainc.com
Website: www.veritaspharmainc.com

Further information about the Company is available on our website at www.veritaspharmainc.com  or under our profile on SEDAR at www.sedar.com  and on the CSE website at www.thecse.com

Investor and Public Relations Contact

The CSE has not reviewed, nor approved or disapproved the content of this press release.